-
Mtech Access
Global market access from strategy to implementation
Start your project
We provide strategy and solutions to help Pharma and Medtech companies bring interventions to market, providing more patient choice and meeting the needs of the healthcare environment.
Our consultants and technical experts support global teams and affiliates throughout the product life cycle, from evidence generation and strategy to communication of value.
We support international market access teams in these key launch markets
United Kingdom
Germany
France
Italy
Spain
Canada
USA
Australia
China
Japan
CASE STUDY
Delivering on global market access strategy, evidence generation and communication objectives
Our client’s global market access team were looking for a consultancy who could support them from strategy to implementation. As the client was in the early stages of developing a new product, they first wanted to understand the challenges and opportunities that their new treatment would face when launching in different markets.
Get in touch
View our client testimonials
Download our Mtech Access Brochures
Download a PDF brochure and share the Mtech Access story with colleagues
To discuss your requirements with our experts, get in touch using the form below.
Latest news
At Mtech Access we are always striving to engage with the wider market access community and share our thoughts on the latest industry issues or methods development.
We're thrilled to announce that Mtech Access will be exhibiting at the ISPOR conference May 5–8 in Atlanta, Georgia, USA! As regular attendees of ISPOR Europe, we're excited to be...
Read More
What can we expect to see in primary care in the NHS given recent policy announcements and ongoing uncertainty? What does the new GP Contract tell us about the future...
Read More
Hannah Palin (Director – Market Access) and Calum Jones (Associate Director – Health Economics) explore the landscape for economic evaluation in the US and highlight important considerations for companies seeking to infiltrate this key market.
We delve into ICER’s influence on drug pricing and access in the US. We also explore the importance of maximising engagement with ICER for favourable pricing and access outcomes.